American Association for Cancer Research
21598290cd120042-sup-f4_203k.pdf (203.91 kB)

Supplementary Figure 4 from Chimeric Transcript Generated by cis-Splicing of Adjacent Genes Regulates Prostate Cancer Cell Proliferation

Download (203.91 kB)
journal contribution
posted on 2023-04-03, 20:23 authored by Yanmei Zhang, Mei Gong, Huiling Yuan, Hong G. Park, Henry F. Frierson, Hui Li

PDF file - 203K, Expression of wild type SLC45A3 and ELK4 in LNCaP cells with CTCF silencing



Gene fusion is a common event in cancer. The fusion RNA and protein products often play causal roles in tumorigenesis and therefore represent ideal diagnostic and therapeutic targets. Formerly, fusion chimeric products in cancer were thought to be produced solely by chromosomal translocation. Here, we show that a chimeric SLC45A3-ELK4 RNA is generated in the absence of chromosomal rearrangement. We showed that it is not a product of RNA trans-splicing, but formed by cis-splicing of adjacent genes/read-through. The binding of CCCTC-binding factor (CTCF) to the insulator sequences inversely correlates with the expression of the chimera transcript. The SLC45A3-ELK4 fusion, but not wild-type, ELK4 plays important roles in regulating cell growth in both androgen-dependent and -independent prostate cancer cells. The level of the chimeric transcript correlates with disease progression, with the highest levels in prostate cancer metastases. Our results suggest that gene fusions can arise from cis-splicing of adjacent genes without corresponding DNA changes.Significance: With the absence of corresponding DNA rearrangement, chimeric fusion SLC45A3-ELK4 transcript in prostate cancer cells is generated by cis-splicing of adjacent genes/gene read-through instead of trans-splicing. SLC45A3-ELK4 controls prostate cancer cell proliferation, and the chimera level correlates with prostate cancer disease progression. Cancer Discov; 2(7); 598–607. ©2012 AACR.Read the Commentary on this article by Kumar-Sinha et al., p. 582.This article is highlighted in the In This Issue feature, p. 569.

Usage metrics

    Cancer Discovery



    Ref. manager